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Primary human hepatocytes (PHHs) are an essential tool for mod-
eling drug metabolism and liver disease. However, variable plating
efficiencies, short lifespan in culture, and resistance to genetic
manipulation have limited their use. Here, we show that the
pyrrolizidine alkaloid retrorsine improves PHH repopulation of
chimeric mice on average 10-fold and rescues the ability of even poorly
plateable donor hepatocytes to provide cells for subsequent ex
vivo cultures. These mouse-passaged (mp) PHH cultures overcome
the marked donor-to-donor variability of cryopreserved PHH and
remain functional for months as demonstrated by metabolic as-
says and infection with hepatitis B virus and Plasmodium falcipa-
rum. mpPHH can be efficiently genetically modified in culture,
mobilized, and then recultured as spheroids or retransplanted to
create highly humanized mice that carry a genetically altered he-
patocyte graft. Together, these advances provide flexible tools for
the study of human liver disease and evaluation of hepatocyte-
targeted gene therapy approaches.
liver | primary human hepatocytes | humanized mice | hepatotropic
pathogens | hepatitis B virus
Hepatocytes, the predominant cell type in the liver, performmultiple functions and play essential roles in metabolic re-
actions and drug clearance (1, 2). In addition, human hepato-
cytes are the exclusive host for several hepatotropic pathogens,
including hepatitis B virus (HBV), hepatitis C virus, and malaria-
causing Plasmodium parasites (3). Therefore, hepatocytes are
central players in many of the world’s leading disease etiologies.
Primary human hepatocytes (PHHs) isolated from human liver
are the gold standard for studies of hepatocyte biology. However,
current PHH options suffer from donor-to-donor variability, lim-
ited availability of high-quality donors, high financial cost to iso-
late and procure, and failure to maintain long-term function in
culture. Furthermore, the inability to isolate high-quality PHH
from patients with liver disease has precluded the study of possible
causal genetic variants in a physiologically relevant model.
Underpinning these limitations is the inability of PHHs to
proliferate once isolated, despite their capacity for regeneration
and expansion in vivo in response to injury. Renewable sources
of human hepatocytes have been sought, including differentia-
tion of pluripotent stem cells into hepatocyte-like cells (HLCs).
Despite the potential of this approach, including the ability to
generate patient-specific hepatocytes from induced pluripotent
stem cells, current HLCs resemble fetal hepatoblasts rather than
mature hepatocytes (4, 5). Protocols have been developed to
expand PHH, including ex vivo growth as organoids (6) or im-
mortalization (7, 8). A more widely adopted approach involves
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PHH transplantation into immunodeficient mice with various
forms of liver injury to provide a niche and milieu that favors
PHH engraftment and expansion. There are several widely used
murine models, including immunodeficient Fah−/− NOD Rag1−/−
Il2rgnull (FNRG) mice (9–11) in which liver injury is induced by
withdrawing the protective drug 2-(2-nitro-4-(trifluoromethyl)
benzoyl)cyclohexane-1,3-dione (NTBC) (12). While the specific
stimuli remain unidentified, this expansion method is presumed
to function via the provision of signals derived from the damaged
mouse liver and by creating vacant space that is liberated as
murine hepatocytes die. Collectively, this environment allows
transplanted human hepatocytes to engraft within the damaged
scaffold and proliferate to repopulate the mouse liver paren-
chyma. Once these chimeric livers are highly humanized, human
hepatocytes can be reisolated. However, to date, these chimeric
models have suffered from the same detractors that limit the use
of unexpanded PHH: most PHH donors repopulate poorly, and
the level of chimerism is variable between animals.
Here, we describe a protocol that, by improving chimeric
mouse liver humanization, enables the expansion of the usable
PHH donor pool. Specifically, we show that, via this protocol,
mouse-passaged primary human hepatocytes (mpPHHs) can
successfully establish long-term cultures that are suitable for drug
metabolism studies and are also susceptible to human hepato-
tropic pathogen infections. Notably, we observe that even poorly
plateable PHHs can be passaged via humanized mouse expansion
and that this process seems to normalize the subsequent plate-
ability of almost every mpPHH tested. Perhaps most significantly,
mpPHH can be efficiently transduced with lentiviral vectors, mo-
bilized, and replated for use in ex vivo applications or retrans-
planted to generate humanized mice that carry a genetically
modified human graft, opening doors for the experimental study of
human liver biology at a level that has thus far been unachievable.
Results
Retrorsine Improves Human Hepatocyte Repopulation in Liver
Chimeric Mouse Models. To reliably study PHH in vivo in liver
chimeric mice or isolate the human graft for ex vivo studies, a
minimum level of humanization is required. For most applica-
tions, the minimum level is ∼10%, which corresponds to 103 μg/mL
serum human albumin (hAlb), an established surrogate marker
for liver humanization (9, 10, 13). Unfortunately, with current
protocols, PHHs from most donors engraft poorly, and few mice
achieve the degree of humanization required for further use. To
address this limitation, we sought to establish protocols where
the majority of PHH donors consistently generate mice with over
10% chimerism.
In rats, the pyrrolizidine alkaloid retrorsine enhances liver
repopulation with donor hepatocytes after partial hepatectomy
or carbon tetrachloride administration (14, 15). We, therefore,
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Fig. 1. Retrorsine improves liver repopulation of FNRG mice with PHHs. (A) Experimental schematic of FNRG mice treated with retrorsine 4 and 2 wk prior to
transplantation with cryopreserved PHHs and NTBC cycling. (B) Serial hAlb measurement in serum of transplanted mice shows higher peak hAlb values in
retrorsine preconditioned (squares) than vehicle control mice (circles). Median ± SEM, t test of end points. PHH1 n = 2 per group, PHH2 n ≥ 4 per group, and
PHH3 n ≥ 7 per group. Estimated percentage of liver humanization is shown in gray. *P < 0.05; ***P < 0.001. (C) Livers from retrorsine preconditioned PHH1
transplanted animals contain larger human areas by FAH staining than vehicle control mice. (Scale bars: Left, 1 mm; Right, 100 μm.) (D) hAlb levels in serum
reached a higher plateau in retrorsine than vehicle preconditioned FNRG mice with 12 of 13 PHH donors ranging from 2- to 30-fold. Symbols are median hAlb
per group of two to five transplanted mice. Color-matched numbers indicate animal numbers that reached hAlb plateau (for vehicle, numbers are shown on
the left, and for retrorsine, they are on the right). (E) Retrorsine works in a dose-dependent manner, with the first dose having the largest benefit on peak
serum hAlb values in PHH2 transplanted FNRG mice. Symbols are individual mice, median ± range, t test. (F) Serum hAlb values peak higher in mice receiving
retrorsine at ZT0 than ZT12 prior to PHH2 transplantation (Left), while PHH3 engrafted faster in mice that received at ZT0 than ZT12 as illustrated by day
42 hAlb values (Right). Symbols are individual mice, median ± range, t test.
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tested if preconditioning FNRG mice with two injections of
retrorsine before PHH transplantation (Fig. 1A) enhanced hAlb
levels in mouse serum. Across PHH from three donors, retro-
rsine improved hAlb levels (Fig. 1B) without affecting animal
survival (SI Appendix, Fig. S1A). Retrorsine increased peak hAlb
levels by 23- and 30-fold in mice engrafted with poor donors
PHH1 and PHH2, respectively (Fig. 1B). In contrast, retrorsine
had only a minor effect (twofold increase) on mice engrafted
with PHH3, an efficient donor that humanizes well even with a
standard protocol (vehicle control). Consistent with hAlb levels,
histological staining for fumarylacetoacetate hydrolase (FAH)
demonstrated that the liver parenchyma of retrorsine-treated
humanized Fah−/− NOD Rag1−/− Il2rgnull (huFNRG) mice was
largely replaced by human hepatocytes (Fig. 1C). We then tested
10 additional PHH donors and found that 9 of them reached
higher peak hAlb levels after retrorsine preconditioning. Across
13 donors, retrorsine on average resulted in 9.5-fold higher peak
serum hAlb levels than vehicle control mice (P = 0.003) (Fig.
1D). This finding confirms that retrorsine preconditioning im-
proves engraftment across a wide range of PHH donors.
We then tested if retrorsine also improved humanization with
fetal hepatoblasts, which require human oncostatin-M (hOSM)
supplementation for efficient repopulation of FNRG livers (13).
To supplement hOSM, we created AAV8-hOSM vectors that, at
low doses, were not toxic and improved humanization (SI Appendix,
Fig. S1B). As with PHH, we found that retrorsine preconditioning
of FNRG mice improved fetal hepatoblast repopulation (SI Ap-
pendix, Fig. S1C).
The scale of retrorsine effects on PHH engraftment varied with
the dose such that one dose led to a large improvement and a
second dose conferred a small additional benefit (Fig. 1E). For
PHH3, there was no benefit of administering a third dose (1.02-fold
increase in serum hAlb, n = 11 two doses vs. n = 9 three doses, P =
0.98). In rat models, retrorsine is bioactivated by CYP450 enzymes
(16, 17), many of which are under circadian regulation. We, there-
fore, examined whether injecting mice with retrorsine at different
times of the day influences its effectiveness. Interestingly, retrorsine
administered at Zeitgeber time 0 (ZT0) resulted in fivefold higher
(PHH2) or faster rise in hAlb (PHH3) than at ZT12 (Fig. 1F).
We hypothesized that retrorsine impaired mouse hepatocyte
proliferation, limiting restoration of the damaged mouse liver
and giving PHH a repopulation advantage. In the Fah−/− model,
this effect can best be observed after animals are being cycled
back on NTBC, when proliferation-based liver restoration by
mouse hepatocytes takes place. To test our hypothesis, livers
from untransplanted FNRG mice were harvested at various
times after NTBC withdrawal and reintroduction (SI Appendix,
Fig. S2A). Histological examination did not show morphological
differences between retrorsine and vehicle preconditioned livers
at the end of NTBC withdrawal or 3 d after restarting NTBC (SI
Appendix, Fig. S2B). To quantify proliferating hepatocytes, livers
were stained for the cell cycle marker Ki67. As expected, few
hepatocytes expressed Ki67 in mice that were off NTBC. On
NTBC reintroduction, Ki67 was more frequently detected in
hepatocytes of retrorsine than vehicle-treated animals, which was
mostly pronounced on day 17 (SI Appendix, Fig. S2C). This did
not support our hypothesis. We then tested whether retrorsine
caused increased mouse hepatocyte senescence or a ductular
reaction, and FNRG livers were stained for p21 or cytokeratins
(CKs), respectively (18). No enhanced hepatocyte senescence or
ductular reaction was observed in mice that received retrorsine
compared with vehicle, making these unlikely mechanisms to
explain the increased humanization phenotype. We then
screened untransplanted FNRG livers for murine growth factors
at the end of the NTBC withdrawal cycle (day 14) or 3 d after
restarting NTBC (day 17). Numerous growth factors and re-
ceptors could be detected at the end of the NTBC withdrawal
cycle, a few of which varied slightly in livers of mice that had
received retrorsine from livers of mice preconditioned with ve-
hicle (SI Appendix, Fig. S2D). These combined observations
suggest that retrorsine promotes PHH repopulation through
mechanisms that are distinct from the cell cycle inhibition ob-
served in rat hepatocytes and may involve an altered growth
factor milieu that is beneficial to human graft expansion.
To extend the application of retrorsine beyond the Fah−/− model,
we next tested whether retrorsine also improved engraftment in two
other chimeric animal models: immunodeficient thymidine kinase
(TK) (19) and hemizygous urokinase plasminogen activator (uPA)+/−
transgenic mice. Using the PHH2 donor for transplantation, we
found that retrorsine preconditioning increased peak hAlb levels by
28-fold in TK recipient mice (SI Appendix, Fig. S1D), consistent with
the Fah−/− model. In uPA+/− mice, which are known to suffer from
graft loss (20) over time, the graft persisted in retrorsine-treated mice
as illustrated by hAlb remaining above 103 μg/mL for months (SI
Appendix, Fig. S1E). These data show that retrorsine preconditioning
improved humanization in three widely used chimeric mouse models
with the large majority of human donors.
Isolation of PHHs from Chimeric Mouse Livers. Retrorsine pre-
conditioning greatly increased the availability of highly human-
ized mice. Since human hepatocytes can be isolated from
chimeric livers (9, 11, 21), we established protocols to enrich for
live human hepatocytes from these livers. Retrorsine precondi-
tioned huFNRG mice were taken off the protective drug NTBC
(12) at least 7 d before harvest. We perfused huFNRG livers and
purified hepatocyte suspensions by Percoll and low-speed cen-
trifugations to enrich for live hepatocytes (mpPHH) (Fig. 2A).
Flow cytometry on mpPHH isolated from moderately (1.1 ×
103 μg/mL hAlb) and highly (1.2 × 104 μg/mL hAlb) repopulated
huFNRG mice showed that our isolation/purification protocol
yielded predominantly human hepatocytes independent of the
extent of liver humanization (Fig. 2B). Collectively, we perfused
84 huFNRG livers and after purification, analyzed the cells by
flow cytometry to measure the expression of human and murine
markers. In 78 mice (93%), this protocol yielded mostly human
cells (Fig. 2C). To obtain high yields, we perfused livers from
retrorsine preconditioned highly chimeric huFNRG mice based
on hAlb serum levels around 104 μg/mL. Liver perfusions of
70 huFNRGmice yielded on average 75 million mpPHH per liver,
ranging from 0.4 to 240 million (Fig. 2D). These data show that
our isolation/purification protocol results in consistently large
numbers of predominantly human hepatocytes isolated from
highly chimeric huFNRG mice.
Freshly Isolated mpPHHs Overcome Donor Variability and Form Long-
Term Cultures.Cryopreserved PHHs from different donors vary in
their ability to engraft in mice and form cultures. We trans-
planted six cryopreserved PHH donors (PHH2 to PHH7) into
FNRGmice without preconditioning and followed repopulation by
serum hAlb. Mice transplanted with PHH3 had the highest median
hAlb (Fig. 3A). Based on these findings, unless otherwise indicated
for subsequent experiments, we used retrorsine preconditioned
FNRG mice transplanted with PHH3. Perfusion yielded on aver-
age 150 times more mpPHH than input cryopreserved PHH. To
rule out that multiple cell divisions in chimeric livers affect
mpPHH quality, we compared liver repopulation following adoptive
transplantation and hepatocyte stability after plating to cryo-
preserved PHH (Fig. 3B). To test the repopulation potential as
previously shown by Azuma et al. (9), equal numbers of cryo-
preserved PHH3 or freshly isolated mpPHH3 were transplanted
into FNRG mice. mpPHH3 exhibited superior repopulation ki-
netics compared with cryopreserved PHH based on faster hAlb
kinetics, although both groups reached similar peak values (Fig.
3C). We concluded that mpPHH retained high repopulation
potential on one round of adoptive transplantation, allowing for
expansion of cryopreserved PHH by over 20,000-fold.
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To determine how closely mpPHH resembled cryopreserved
PHH, we compared the transcriptomes of mpPHH3 suspensions
from five humanized livers with two aliquots of cryopreserved
PHH3. Both groups had similar expression of genes related to
Phase I and Phase II detoxification pathways as well as many
other liver-specific genes (SI Appendix, Fig. S3).
We then evaluated if mpPHH could form stable cultures (22)
by using hAlb in culture supernatant as a marker for culture
stability. Whereas cryopreserved PHH from three donors
(PHH2, PHH3, PHH4) formed cultures that showed variable
and modest levels of hAlb secretion that decreased over time,
passaging these donors through mice yielded large numbers of
hepatocytes that formed robust cultures with high and stable
hAlb over time (Fig. 3D). Next, we characterized the long-term
stability of mpPHH cultures. We found that denser mpPHH
cultures formed confluent monolayers and were stable for at
least 8 wk as shown by hAlb and 4 wk by multiple other read-
outs (SI Appendix, Fig. S4). We optimized these conditions for
various plating formats (Methods). Because some nonplateable
donors engrafted beyond 103 μg/mL hAlb levels in retrorsine
preconditioned mice (SI Appendix, Fig. S5A), we cultured non-
plateable PHH8 and plateable PHH2 before and after passaging
through mice. Whereas plateable PHH2 formed cultures both
in vitro and ex vivo, nonplateable PHH8 only attached ex vivo (SI
Appendix, Fig. S5B).
Similar to the flow cytometry data on freshly isolated mpPHH
(Fig. 2 B and C), the vast majority of cells after plating were
human hepatocytes as assessed by human CK18 and nuclear
mitotic apparatus protein (NuMA) staining (Fig. 3E).
These data show that passaging cryopreserved PHH through
retrorsine preconditioned huFNRG mice yielded large numbers
of mpPHH that could be plated, resulting in robust and stable
cultures and hence, overcoming marked donor-to-donor varia-
tion in plateability of cryopreserved PHH.
Drug Metabolism and Infection Studies in Long-TermmpPHH Cultures.
To exploit the stability of mpPHH cultures, we tested their po-
tential for preclinical drug safety studies and evaluation of drug
induction potential. First, we observed that Phase I CYP450
activity is retained in mpPHH cultures as seen by the stability of
CYP3A4 levels measured in two different mpPHH donors
(mpPHH3 and mpPHH4) for at least 1 mo postplating (Fig. 4A).
Next, we determined whether mpPHHs maintain the ability to
induce CYP450 activity after long-term culture by exposing the
cells to 25 μM rifampicin, a known inducer of CYP3A4. Ri-
fampicin treatment for 48 and 96 h induced CYP3A4 activity by
5- to 10-fold in a time-dependent manner (Fig. 4B). We then
tested if enzyme activity of CYP3A4 could be modulated by
RNA interference (RNAi)-mediated knockdown. To this end,
mpPHHs were treated with CYP3A4-targeting small interfering
RNA (siRNA) or nontargeting control for 24 h, and enzyme
activity was monitored for up to 20 d posttreatment. Notably,
CYP3A4 activity remained silenced during the long-term culture
of mpPHH (Fig. 4C). Finally, to evaluate their use for toxicolog-
ical studies, we exposed mpPHH to serial dilutions of four known
hepatotoxic compounds and plotted their effect on hAlb secretion
as a cell injury readout (Fig. 4D). We selected drugs that are
metabolized by different enzymes (CYP3A4, CYP2E1, CYP2C9,
A
B C
D
Fig. 2. Isolation of PHHs from liver chimeric mice. (A) Graphic representation of engrafting FNRG mice with cryopreserved PHH followed by perfusion and
purification to yield mpPHH suspensions. (B) Flow cytometry of mpPHH after isolation and purification from a moderately or highly huFNRG mouse. The
isolation protocol yields few mouse CD81 (mCD81-PE)-positive hepatocytes and even fewer in highly engrafted huFNRG mice. (C) Percent HLA-I+ vs. mCD81+
hepatocytes from 84 individual huFNRG mice were analyzed by flow cytometry. Most mice (n = 78, brown symbols) yielded predominantly human hepa-
tocytes. (D) Serum hAlb levels of 70 individual huFNRG mice (circles) were plotted against mpPHH yield per mouse. On average, 75 million (range from 0.4 to
240 million) viable mpPHHs were recovered from huFNRG mice.
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and CYP1A2) and observed dose-dependent hepatotoxicity on a
24-h treatment. Taken together, these experiments suggest that
mpPHHs are suitable for long-term drug metabolism and drug
safety studies.
Next, we tested whether mpPHH cultures could support in-
fection and propagation of Plasmodium falciparum (Pf) and HBV,
two prevalent hepatotropic pathogens that exclusively infect hu-
man hepatocytes. To determine mpPHH permissiveness to Pf, we
used parasite entry assays and staining with Pf-specific antibodies
with or without cell permeabilization. This allowed us to distin-
guish parasites that only bound to the cell surface from those that
invaded the cells. On average, 11% of Pf parasites successfully
invaded hepatocytes (Fig. 4E). We then monitored parasite
growth over time by measuring the intracellular area occupied by
individual parasites and found that parasites increased in size
from days 2 to 4 postinfection (Fig. 4F). Together, these data
showed that mpPHHs support efficient infection and development
of Pf parasites.
The chronic phase of HBV infection cannot readily be re-
capitulated in cell culture due to the short lifespan of current
PHH systems. We took advantage of the longevity of mpPHH
cultures to monitor HBV infection parameters for up to 8 wk
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Fig. 3. Freshly isolated mpPHHs engraft and plate more efficiently than cryopreserved PHHs and overcome donor-to-donor variability. (A) Serum hAlb
levels in FNRG mice after transplantation with six different cryopreserved donors (PHH2 to PHH7). Median ± range hAlb levels of groups of five
transplanted mice. Three to five mice per group survived until day 76. Estimated percentage of liver humanization is shown in gray. (B) Graphic re-
presentation of passaging PHH through mice for adoptive transfer and plating for ex vivo cultures. (C ) Comparison of cryopreserved PHH3 vs. freshly
isolated mpPHH3 for repopulation of FNRG mice as shown by serum hAlb levels over time. Freshly isolated mpPHH3 repopulates faster than cryopreserved PHH3.
Median ± range hAlb levels of groups of nine transplanted mice. Six to eight mice per group survived until day 87. t test between groups of individual
timepoints. (D) Cryopreserved (closed circles) and freshly isolated mpPHHs (open circles) of the same three donors (PHH2: green; PHH3: blue; and PHH4:
orange) were cultured for 13 d. Media were changed every 2 d, and hAlb levels were measured over time. The data represent at least five biological
replicates per donor and are presented as mean ± SD. (E ) Freshly isolated mpPHHs were plated. After fixation with 4% paraformaldehyde, cells were
stained with human markers CK18 (red) and NuMA (green). Nuclei were stained with DAPI. Most cells were positive for one or both of the human markers,
except for cells indicated by white arrows. (Magnification: 20×.)
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Fig. 4. mpPHH cultures are suitable for long-term drug metabolism and infection studies. (A) CYP3A4 activity was stable over time in mpPHH. Freshly isolated
mpPHHs derived from two donors (PHH3 and PHH4) were seeded in 96-well plates. CYP3A4 activity was measured from day 15 until day 29 postseeding, and
values (mean ± SEM, n = 3) were plotted as percent activity relative to day 15. (B) Rifampicin induces CYP3A4 activity. Cells were cultured in 96-well plates and
treated with 25 μM rifampicin for 48 and 96 h on day 11 or 14 postseeding. CYP3A4 activity was measured as in A. Data (mean ± SEM, n = 3) were plotted as
fold change relative to untreated samples. A representative of two independent experiments is shown. *P = 0.0457 and **P = 0.0026 for 48 and 96 h, re-
spectively; one-way ANOVA. (C) siRNA silencing of CYP3A4. Cells were cultured in 96-well plates and treated with 50 nM siRNA (either nontargeting control or
targeting CYP3A4) for 24 h. Silencing efficiency was determined every 2 to 3 d by measuring CYP3A4 activity as in A. Data (mean ± SEM, n = 3) were plotted as
fold change relative to the nontargeting control. P < 0.0001; two-way ANOVA. A representative of three independent experiments is shown. (D) Drug
hepatotoxicity in mpPHH cultures. Cells were cultured in 96-well plates and treated with increasing concentrations of drugs for 24 h. The supernatants were
harvested, and levels of secreted hAlb were measured by ELISA. Data were normalized to drug-free controls. The graph represents the mean ± SEM of three
independent experiments (n = 3). The four drugs are metabolized by different CYP450 enzymes: acetaminophen (yellow), CYP2E1 and CYP3A4; atorvastatin
(blue), CYP3A4; diclofenac (red), CYP2C9; and clozapine (purple), CYP1A2. (E) Cells were seeded in 96-well plates and infected 1 wk later with 10,000 Pf
sporozoites per well isolated from infected mosquitoes. The percentage of invaded sporozoites at 3 h postinfection was determined with sequential im-
munofluorescence staining using PfCSP antibodies. Noninvaded sporozoites are detected as yellow and invaded parasites are detected as red after cell
permeabilization. Values (mean ± SEM, n = 6) represent one of two independent experiments. (F) Cells infected with 40,000 Pf sporozoites per well were
monitored for several days. Media were changed every 2 d, and cells were stained for PfHSP70 (red) after 2 and 4 d postinfection. Parasite intracellular
development was monitored by measuring the area occupied by parasites (each dot represents a single invading parasite); 30 to 50 parasites per well were
scored (n = 3). Data shown represent one of two independent experiments. (G) Cells were seeded in 96-well plates and infected with 50 GEQ per cell HBV
on day 0. Media were changed every 4 d, and HBeAg levels measured and plotted over time from day 5 until day 57 postinfection. Data from three biological
replicates are represented as mean ± SEM. PEI, Paul Ehrlich Institute. (H) Cells seeded in 24-well plates were infected with 300 GEQ per cell HBV. Media were
changed every 2 d, and cells were fixed and stained for HBcAg after 4 wk (HBcAg: red; nuclei: blue).
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postinfection. Hepatitis B virus e antigen (HBeAg) was detected
in the supernatant of 96-well cultures for 8 wk (Fig. 4G). In
addition, at 1 mo postinfection, robust expression of hepatitis B
virus core antigen (HBcAg) illustrated widespread infection of
mpPHH (Fig. 4H). In summary, mpPHH supported HBV in-
fection for at least 2 mo.
Since mpPHH were amenable to pathogen infections and drug
toxicity studies, we adapted the system to a microscale 384-well
format suitable for high-throughput screens. As a proof of con-
cept, we infected cells with HBV and treated a fraction of the
wells with the HBV entry inhibitor Myrcludex B. Ten days
postinfection, naïve but not Myrcludex B-treated cells were ef-
ficiently infected with HBV as evidenced by secreted HBeAg and
HBcAg expression (SI Appendix, Fig. S6).
These combined data illustrate that the long-term stability of
mpPHH expands research into various human hepatocyte func-
tions that cannot accurately be studied in short-term cultures.
Lentiviral Transduction of mpPHH Generates Transgenic Spheroids
and Chimeric Mice. One of the major limitations of PHH is their
resistance to efficient genetic manipulation. This stems in part
from widespread observations that two-dimensional (2D) PHH
cultures cannot survive mobilization, therefore impairing sub-
sequent applications. Given the stability of mpPHH cultures, we
aimed to establish protocols to efficiently transduce hepatocytes
with lentiviral vectors using red fluorescent protein (RFP) as proof
of concept. In addition, we sought to overcome the much larger
hurdle of mobilizing transduced mpPHH and either reculture or
humanized
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Fig. 5. Cultured mpPHH can be mobilized and either recultured or retransplanted, creating a modified human graft for in vitro and in vivo applications. (A)
Schematic representation of lentivirus transduction of mpPHH and subsequent detachment for reculturing or retransplantation. Transduced cells are shown in
red. (B) mpPHHs were cultured in 12-well plates, and media were changed every 2 d for 3 wk. Cells were then mobilized and reseeded in new plates. Media
were changed every 2 d for an additional week. Representative images from cultures before and after detachment and replating are shown. (C) hAlb levels
from supernatants from the initial cell culture (dark yellow) and the replated cells (light yellow) were measured and plotted over time. Data from six bi-
ological replicates are represented as mean ± SEM. (D) mpPHHs were transduced with RFP-expressing lentivirus and imaged after 3 d. (E) mpPHHs were
cultured in six-well plates and transduced with RFP/puro-expressing lentiviruses. Untransduced or transduced with a G418-expressing lentivirus was used as
controls. After 3 d, cells were treated with puromycin for 5 d. Cells were detached and transplanted into FNRG mice. Serum hAlb levels 10 wk after trans-
plantation are displayed for individual mice. t test between groups. *P < 0.05; ****P < 0.0001. (F) mpPHHs were transduced with RFP/puro-expressing
lentiviruses and after 3 d, treated with different concentrations of puromycin for 5 d. Cells were detached and transplanted into FNRGmice. Serum hAlb levels rose
similarly between groups. Median ± range hAlb levels of groups of 9 to 12 transplanted mice. Three to six mice per group survived until day 132. (G) Mouse livers
from E were perfused, and mpPHHs were isolated. These cells were analyzed by flow cytometry to quantify RFP expression. (Magnification: B and D, 20×.)
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retransplant these modified hepatocytes to create huFNRG mice
with a genetically manipulated graft, as depicted in Fig. 5A.
To this end, lentiviral-infected mpPHH cultures were moni-
tored for 3 wk, after which cells were detached and replated.
Between 60 and 80% of mpPHHs survived this process and also,
successfully established healthy 2D cultures (Fig. 5B) with similar
hAlb levels as before detachment (Fig. 5C). We then defined
conditions at which more than 90% of mpPHHs were transduced
with RFP-lentiviral vectors (Fig. 5D).
We combined these two technical advances for two applica-
tions. In the first case, we attempted to create three-dimensional
(3D) spheroid hepatocyte cultures, similar to those we routinely
achieve via plating mpPHH in U-bottom 96-well plates. However,
we observed that lentiviral RFP transduction of preformed
spheroids was consistently inefficient (SI Appendix, Fig. S7A). To
overcome this problem, we first transduced mpPHH in 2D, de-
tached the cells, and then created spheroid cultures. Following this
protocol, more than 90% of the spheroid cells were RFP positive
(SI Appendix, Fig. S7 B and C). In addition, by titrating the seeding
density, we obtained spheroids of different size (SI Appendix, Fig.
S7D). As a second application, we sought to generate liver chi-
meric mice with a modified human graft. To this goal, we trans-
duced mpPHH with RFP puromycin resistance (RFP-puro-lenti)
or G418 resistance-conferring lentiviral vectors. After 5 d of pu-
romycin treatment in culture, mpPHHs were mobilized into single-
cell suspensions and transplanted into FNRG mice. Five weeks
posttransplantation, we detected hAlb in mice transplanted with
RFP-puro-lenti transduced mpPHH regardless of puromycin se-
lection, suggesting that mpPHH tolerated the selection process.
As expected, both RFP-G418-lenti transduced and untransduced
mpPHH cultures did not survive puromycin treatment as indicated
by minimal serum hAlb levels 5 wk after transplantation (Fig. 5E).
To further optimize repopulation of modified mpPHH in
FNRG mice, cells were transduced with concentrated RFP-puro-
lenti and then treated with 0, 2, and 5 μg/mL puromycin. All mice
reached high serum hAlb levels irrespective of puromycin selec-
tion (Fig. 5F). Four months after transplantation, immunohisto-
chemistry on chimeric livers showed ∼50% human chimerism (SI
Appendix, Fig. S8A), consistent with high serum hAlb values. Flow
cytometry from perfused livers of these mice showed that the
majority of human hepatocytes expressed RFP (Fig. 5G). More-
over, plated mpPHHs from these animals formed stable cultures
and maintained RFP expression (SI Appendix, Fig. S8B).
These data show that mpPHH cultures can be efficiently
transduced in 2D format, detached, and used to create highly
transduced 3D spheroids or humanized mice with robust, per-
sistent, genetically altered grafts.
Discussion
The increased demand for physiologically relevant hepatocyte
systems led the field to develop methods to expand this limited
resource beyond the hepatocytes isolated from human livers.
Different approaches are based on in vitro expansion by trans-
forming PHH or by differentiating stem cells to immature HLCs.
In parallel, in vivo approaches rely on PHH expansion using liver
injury mouse models. We show here that the latter approach ef-
ficiently expanded PHH numbers by about 150-fold per round of
transplantation and reduced the donor-to-donor variability of
cryopreserved PHH in terms of plating efficiency. Retrorsine en-
hanced this process, particularly for poor donors that otherwise
cannot be studied in cell culture. We are unsure of the mechanism
by which retrorsine improves humanization. In untransplanted
FNRG mice cycled off NTBC, retrorsine enhanced mouse hepa-
tocyte Ki67 expression after restarting NTBC and modestly in-
creased intrahepatic FGF7 and EGFR protein levels but did not
change p21 expression or cause a ductular reaction. These data are
consistent with observations in wild-type mice (23) and distinct
from those in rats (14), suggesting that mechanisms may differ
from the impaired hepatocyte proliferation widely observed in rats.
Freshly isolated mpPHHs reliably formed cultures that could
be maintained for months, which contrasts with previously
reported short-term cultures (9). The combination of retrorsine
preconditioned huFNRG mice and Percoll enrichment resulted
in mpPHH cultures composed of mostly human hepatocytes.
Since we did not magnetically deplete mouse cells (21), the long-
term stability may, however, depend on a small fraction of un-
defined mouse stromal support cells. These cultures advance
research across a wide spectrum of human hepatocyte biology.
For example, following HBV infection and spread for 8 wk al-
lows for studies into the molecular mechanisms by which HBV
establishes chronicity. A second application is the adaptation to a
384-well microscale mpPHH format. This will facilitate high-
throughput genetic and compound screens in human hepato-
cytes. Additionally, because yields from chimeric mice are high
and mpPHH cultures are robust, plated cells were easily shipped
to collaborators who then conducted drug metabolism and
Plasmodium infection studies. This illustrates that mpPHH can
be widely used by the research community without the need to
set up logistically complex chimeric mouse colonies.
The most significant advance of our systems is the ability to
efficiently genetically manipulate mpPHH. Although lentiviral
manipulation of hepatocytes prior to transplantation has been
reported, transduction remained very inefficient (24, 25) (in our
laboratory, 5 to 10%). Once plated, PHHs do not proliferate and
were generally believed to resist further applications, such as ex-
pansion in chimeric mice. Our systems to transduce mpPHH, se-
lect transduced cells with puromycin, mobilize these cells, and
then either create spheroid cultures or repopulate huFNRG mice
to high chimerism have many implications for the study of hepa-
tocyte biology. It allows for the efficient modifications of mpPHH
in vitro by either overexpressing or knocking down genes of in-
terest. These modified mpPHHs can then be expanded in mice for
in vivo studies, or chimeric mice can be subjected to manipula-
tions, such as infections or diets, and their mpPHHs can sub-
sequently be harvested for in vitro applications. This versatile
system will allow for disease-specific genetic manipulations linked
to liver physiology and hepatocyte-specific interactions. It will al-
low for the creation of disease-specific human hepatocyte systems
and will advance the long-term goal of therapeutic hepatocyte
transplantation for human liver conditions.
Methods
Cells. Cryopreserved PHHs were purchased from Triangle Research Labs and
Lonza or were isolated from surgical specimens and cryopreserved in Dulbecco’s
modified eagle medium (DMEM) supplemented with 10% dimethyl sulfoxide
(DMSO) and 20% fetal bovine serum (FBS) (11). Human fetal hepatoblasts were
isolated from fetal liver tissue (Advanced Bioscience Resources, Inc.) as described
previously (13, 26). Briefly, fetal livers were incubated with collagenase con-
taining digestion buffer, and large cells were enriched by density centrifugation
before cryopreservation. The use of human materials was approved by the
Rockefeller University Institutional Review Board; however, was exempted of
informed consent under category 4.
Mice. Fah−/−mice (27) were provided by Markus Grompe, Oregon Health and
Science University, Portland, OR and crossed to NOD Rag1−/− Il2rgnull mice
(Jackson Labs) to derive FNRG mice as previously described (11). After the first
NTBC withdrawal cycle, we observed 67.3 ± 17.1% survival in FNRG females
and 1.8 ± 3.6% survival in FNRG males in our facility. Therefore, only FNRG
females were used for these experiments. Thymidine kinase transgenic mice
on the NOD SCID Il2rgnull background (TK-NOG) (19) were obtained from
Taconic Biosciences. Only males were used since female TK-NOG mice do not
support high humanization (19). Immunodeficient SCID mice hemizygous for
the uPA transgene were bred at Ghent University as previously described (28).
Male uPA+/− mice were used, although both genders support humanization.
FNRG mice were maintained on an ad libitum chow diet with amoxicillin and
drinking water containing 16 mg/mL NTBC (Yecuris). TK-NOG and uPA mice
were maintained on regular chow. Mice were housed under a 12-h light cycle
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from 7:00 AM (ZT0) to 7:00 PM (ZT12). All experiments were conducted under
animal use protocols approved by Rockefeller University and Ghent University.
Mouse Preconditioning. Retrorsine (catalog no. R0382; Sigma Aldrich) was
dissolved at 20 mg/mL in 100% ethanol at 56 °C and stored in aliquots at
−20 °C. For intraperitoneal injections, 100 μL (2 mg) retrorsine or 100 μL
ethanol vehicle was diluted with 400 μL phosphate buffered saline (PBS)
without calcium or magnesium (PBS−/−). For Fah−/− and TK-NOG experiments,
retrorsine was administered at 2-wk intervals, typically the first dose at 3 to
4 wk prior to transplantation and a second dose 2 to 3 wk prior to trans-
plantation. In uPA+/− mice, retrorsine was injected 12 to 13 d after birth at
70 mg/kg. For circadian experiments, ZT0 injections were administered between
7:00 AM and 8:00 AM, and ZT12 injections were between 7:00 PM and 8:00 PM.
For hOSM, supplementation of an AAV8-hOSM was created by cloning hOSM
into the pAAV-CB vector expressing hOSM driven by the cytomegalovirus en-
hanced chicken β-actin promoter. Seventy-two hours after cotransfecting this
construct or a control vector expressing firefly luciferase with the pDG8 helper
plasmid into HEK293 cells, virus was purified from cell pellets using an iodixanol
density gradient protocol. Titers were determined by dot blot hybridization as
described previously (29). Mice received the AAV8-hOSM vector through tail
vein injections 7 to 10 d prior to transplantation of human fetal hepatoblasts.
Transplantations. Female FNRG recipients were withdrawn fromNTBC 4 to 5 d
prior to surgery. Male TK-NOG mice 7 wk of age received 48 h of 0.1 mg/mL
valganciclovir (Sigma Aldrich) in drinking water 14 d prior to transplantation
(19). uPA+/− mice were transplanted 8 d after retrorsine injection when they
were 20 to 21 d old. Human cells were transplanted as described previously
(11). Briefly, under sterile conditions and using isoflurane anesthesia, the
skin was cleaned with povidone iodine, and a 0.5- to 1-cm incision was
created over the left flank, after which the peritoneum was mobilized and
opened. The ventral tip of the spleen was mobilized onto the peritoneum,
and human cells were injected into the spleen using a 28-gauge insulin sy-
ringe. After hemostasis was achieved by applying pressure to the injection
site, the peritoneum was closed using 4.0 Vicryl suture (Ethicon) and the skin
was closed using metal Mikron Autoclips (BD Biosciences). Mice received two
doses of postoperative buprenorphine (Abbot Animal Health) 0.05 mg/kg
for analgesia. Metal clips were removed 14 d after surgery.
Liver Perfusion and Hepatocyte Isolation. Hepatocytes were isolated from
chimeric livers as described (11, 29). Briefly, mice were anesthetized with
ketamine/xylazine, and a 24-gauge angiocath was inserted into the inferior
vena cava. Then, the portal vein was cut, and the mouse liver was perfused
sequentially with PBS−/− supplemented with heparin, Hanks buffered saline
solution (HBSS) supplemented with 5 mM ethylenediaminetetraacetic acid
(EDTA) and 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
(Hepes), and finally, HBSS supplemented with 0.05% Type IV collagenase
(Sigma Aldrich) and 1 U/mL DNase (Thermo Fisher). After digestion, the liver
was disrupted over a 70-μm cell strainer, and the cell suspension (50 mL) was
spun at 50 × g for 5 min at 4 °C using an Allegra X-14R Centrifuge (Beckman
Coulter). The supernatant was gently aspirated, and the cells were washed
once with PBS−/−. The cell pellet was resuspended in 10 mL PBS−/− and gently
mixed with equal volume of Percoll working solution (catalog no. 17–0891-
01; GE Healthcare). Percoll working solution consisted of 5.4% 10× PBS−/−,
48.6% Percoll, and 46% William’s E medium (catalog no. 12551–032; Life
Technologies). The cell suspension was spun at 100 × g for 5 min at 4 °C, and
the pellet washed once with PBS. After centrifugation at 50 × g, the cells were
resuspended in PBS and left on ice for 45 min. Then, a second round of Percoll
was used to further purify the cell suspension. The final pellet was resus-
pended in W10 plating medium (William’s E medium [WEM] supplemented
with 10% FBS, 1% penicillin/streptomycin [catalog no. 15140–12; Life Tech-
nologies], 1% 200 mM L-glutamine [catalog no. 25030–081; Life Technologies],
0.1% 50 mg/mL Gentamicin reagent solution [catalog no. 15750–060; Life
Technologies], and 0.1% Corning ITS premix [catalog no. 354350; Corning]),
and viable cells were counted using trypan blue. Viability was usually above
95% without clumps. If clumps were present, the cell suspension was passed
through a 40-μm filter. For adoptive transplant into new FNRG recipient mice,
cells were spun at 50 × g for 5 min at 4 °C and resuspended in cold PBS. For
each mouse, 65 μL of cell suspension of 0.5 to 1 million cells was injected. For
in vitro applications, the cells were kept on ice in W10 plating medium until
seeded in various formats.
Hepatocyte Plating and Maintenance. Once the cells (mpPHH) were isolated
and purified with two rounds of Percoll, they were freshly seeded on collagen-
coated plates (BD Biosciences) in W10 plating medium. The cells were equally
distributed by shaking on a flat surface and then, left on the bench at room
temperature for 45 min. Once the cells settled and evenly distributed, they were
transferred to a humidified 37 °C incubator. Cryopreserved PHHs were first
thawed at 37 °C and then, transferred to 50 mL W10. After centrifugation at
50 × g, the cells were resuspended in W10, counted, and seeded on plates as
described formpPHH. For each plating format, we optimized the seeding density
to achieve confluent cultures. To avoid concentrating cells in the middle of the
well, we seeded the cells with excess medium. The next day, the cells were
washed once with WEM to remove any cell debris and serum. For maintenance
medium, we used hepatocyte-defined medium (HDM; catalog no. 05449; Corn-
ing) supplemented with 1% penicillin/streptomycin, 1% 200 mM L-glutamine,
0.1% 50 mg/mL Gentamicin, and 2% DMSO (catalog no. 4-x-5; ATCC). Unless
otherwise stated, medium was changed every other day. Table 1 summarizes
the different formats with seeding densities and medium volumes.
Lentivirus Transduction. ConfluentmpPHH cultures were transducedwith RFP-
expressing lentiviral pseudoparticles (lentiviral vector SCRPSY expressing red
fluorescent protein [SCRPSY-RFP]) in the presence of 4 μg/mL polybrene by
spinoculation for 1 h at 1,000 × g at 37 °C. Three days posttransduction, RFP
expression reached maximum levels and remained stable over time.
Mobilization of mpPHH for Replating and Retransplantation. Untransduced or
RFP-transduced mpPHH cultures were maintained from days to weeks before
a detachment protocol was applied. Specifically, after multiple washes with
WEM, the cultures were incubated for 30 min with HBSS (catalog no. 14175–
095; Life Technologies) with 10-min interval washes to loosen hepatocyte
tight junctions. Then, the cells were incubated with TrypLE Select (10×; catalog
no. A12177-01; Life Technologies) for 4 to 5 min, and the cells were gently
resuspended in W10 medium. After a 5-min spin at 50 × g, the cells were
resuspended inW10, counted, and replated or retransplanted into FNRGmice.
Spheroid 3D Culture Formation. Confluent mpPHH cultures were transduced
with RFP-expressing lentiviral VSV-G pseudoparticles (SCRPSY-RFP) as de-
scribed above. Ten days later, the cells were detached by brief treatment with
TrypLE, washed, and plated in 100 μL W10 plating medium in Ultra-Low
Attachment U-bottom 96-well plates (catalog no. 7007; Costar). Plates
were centrifuged at 40 × g for 5 min to promote aggregate formation.
Spheroid aggregates formed between 1 and 3 d after plating, at which time
the cultures were switched to serum-free medium. Spheroids of different
size were formed depending on the indicated number of plated cells after
10 d in culture. Spheroid images were acquired on an inverted Zeiss Axiovert
200 microscope fitted with a Perkin-Elmer UltraView spinning disk and
Andor iXon 512 × 512 electron multiplying CCD camera; 100 image slices
were acquired with 3-μm steps in both the bright-field and fluorescent
channels using either transmitted light or 561-nm laser excitation (Spectral
Applied) and a 10× Plan-ApoChromat 0.45 numerical aperture objective.
Image analysis and editing were performed using ImageJ.
siRNA Transfection and CYP3A4 Activity. ON-TARGETplus SMARTpool siRNA
oligonucleotides (CYP3A4, catalog no. L-008169010005; nontargeting control
pool, catalog no. D-001810–10-05; Dharmacon) were delivered to hepato-
cytes using RNAiMAX Transfection Reagent (Thermo Fisher Scientific) per
the manufacturer’s protocols at final concentration of 100 nM in antibiotic-
free media (final volume 100 μL). Triplicate wells containing mpPHH were
exposed to siRNA duplexes overnight for 24 h and subsequently cultured in
supplemented hepatocyte media. Knockdown efficiency was determined by
qRT-PCR using specific CYP3A4 primers and using a cell-based P450-Glo
CYP3A4 Assay with luciferin-IPA (catalog no. V9002; Promega) according
to the manufacturer’s instructions.
Drug Treatments. Acetaminophen (catalog no. A7085; Sigma), diclofenac
(catalog no. D6899; Sigma), clozapine (catalog no. C6305; Sigma), and
Table 1. mpPHH seeding density in various plating formats
Plate format
No. of cells
per well Volume (plating) Volume (maintenance)
384 well 10,000 50 μL 50 μL
96 well 40,000 100 μL 100 μL
24 well 350,000 1.5 mL 0.5 mL
12 well 800,000 2 mL 1 mL
6 well 1,300,000 4 mL 2 mL
Michailidis et al. PNAS Latest Articles | 9 of 11
M
ED
IC
A
L
SC
IE
N
CE
S
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ite
its
bi
bl
io
th
ee
k 
G
en
t o
n 
Ja
nu
ar
y 
9,
 2
02
0 
atorvastatin (catalog no. 10493; Cayman chemical) were dissolved in DMSO
and added to mpPHH cultures at the final concentrations indicated.
Plasmodium Infection and Detection. Pf sporozoites were isolated from sali-
vary glands of Anopheles stephensi bred at John Hopkins University Malaria
Research Institute or Harvard School of Public Health. For the entry assay,
mpPHHs were exposed to 10,000 sporozoites, washed 3 h later with PBS, and
fixed with 4% paraformaldehyde for 15 min at room temperature. After
blocking for 30 min in PBS with 2% bovine serum albumin, parasites were
detected using a sequential double-staining assay. Cells were first incubated
for 1 h with anti-Pf circumsporozoite protein (CSP) antibodies followed by
incubation with secondary antibodies and AlexaFluor 488 for another hour.
After washing, cells were permeabilized with ice-cold methanol for 10 min
at 4 °C and again incubated with anti-PfCSP antibodies and AlexaFluor 594
for 1 h each, with washing in between. Finally, cells were counterstained
with Hoechst 33258 (1:5,000), mounted in Aquamount (Lerner Laboratories),
and analyzed on a Nikon Eclipse Ti fluorescence microscope. For parasite
development assessment, mpPHHs were infected with 40,000 sporozoites,
washed 3 h later, and maintained in hepatocyte media supplemented with
penicillin/streptomycin (300 μg/mL). Cultures were fixed in ice-cold methanol
for 10 min at 4 °C at days 2 and 4 postinfection. Parasites were detected
using Pf heat shock protein 70 (HSP70) antibodies followed by AlexaFluor
594 secondary antibodies for 1 h each. Nuclei and cells were mounted as
described above. Images were captured, and the parasite area was measured
using NIS-Elements Advanced Research imaging software (Nikon).
HBV Infection and Detection. HBV stock was prepared as previously described
(30). Briefly, supernatants from confluent HepDE19 cells (31) (HBV-producing
cells) were harvested every 2 d for 3 wk and concentrated using Centricon Plus-
70 centrifugal filter devices (Millipore-Sigma). The concentrated stock was
aliquoted and kept at −80 °C. The stock concentration was determined as HBV
genome equivalents (GEQ) per milliliter using a TaqMan-based qPCR assay. For
HBV infections, 4 to 5 d after mpPHH seeding the cells were infected with the
indicated concentration of HBV in hepatocyte maintenance medium (HDM
with 2% DMSO) supplemented with 4% polyethylene glycol 8000 (catalog no.
81268–250G; Sigma). The plates were spinoculated for 1 h at 1,000 × g at 37 °C.
After 24 h, the cells were washed 5× with WEM, and maintenance medium
was added. For the 384-well plate format, 500 nMMyrcludex B (32) (HBV entry
inhibitor) was incubated with the inoculum and washed out the next day.
Secreted HBeAg was measured from culture supernatants every 4 d by loading
50 μL into 96-well plates of a chemiluminescence immunoassay kit according
to the manufacturer’s instructions (DiaSino Laboratories Co.). A FLUOstar
Omega luminometer was used to read the plates. HBeAg concentrations are
expressed in Paul Ehrlich Institute units per milliliter. Hepatocyte cultures were
fixed in 4% paraformaldehyde for 20 min at room temperature, washed with
PBS, and permeabilized with 0.1% Triton X-100 for 10 min. After extensive
washing, cells were incubated for 1 h at room temperature with blocking
solution 5% goat serum in PBS (catalog no. 005–000-121; Jackson Immuno-
Research). A rabbit polyclonal anti-HBV core antibody (catalog no. HBP-023–9;
Austral Biologicals) was added to the cells at 1:500 dilution in blocking solution
and incubated at 4 °C overnight. A goat anti-rabbit AlexaFluor 594 (cata-
log no. A-11012; Life Technologies) at a dilution of 1:1,000 was used as a
secondary antibody. Nuclei were stained with DAPI. Cells were imaged using a
Nikon Eclipse TE300 fluorescent microscope and processed with ImageJ.
Immunohistochemistry. Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded murine liver tissues using mouse anti-human FAH
(clone 2; Abcam) (13) and rabbit NuMA (Abcam) staining performed as de-
scribed previously (18). In brief, sections were deparaffinized in xylene (three
changes), rehydrated through graded alcohols (three changes 100% ethanol,
three changes 95% ethanol), and rinsed in distilled water. Antibody incubation
and detection were carried out on a NEXes instrument (Ventana Medical
Systems) using Ventana’s reagent buffer and i-View detection kit. Endogenous
peroxidase activity was blocked with hydrogen peroxide. Heat-induced epitope
retrieval was performed in a 1,200-W microwave oven at 100% power in
10 mM sodium citrate buffer, pH 6.0, for 20 min. Sections were allowed to cool
for 30 min and then, rinsed in distilled water. Mouse anti-human FAH or rabbit
anti-human NuMA was diluted in PBS and incubated overnight at room tem-
perature. Primary antibody was detected with biotinylated goat anti-mouse
followed by application of streptavidin–horseradish peroxidase conjugate. The
complex was visualized with 3,3 diaminobenzidine and enhanced with cop-
per sulfate. Matched immunoglobulin isotype, at equivalent concentra-
tion and diluted in PBS, was used as negative control. On completion of
staining, all slides were washed in distilled water, counterstained with
hematoxylin, dehydrated, and mounted with permanent media. Stained
slides were scanned at 40× magnification using the Leica Microsystems
SCN 400F Whole Slide Scanner. Images were viewed and captured using
SlidePath’s Digital Image Hub (Leica Microsystems).
Enzyme-Linked Immunosorbent Assay (ELISA) for Albumin, Transferrin, and
Alpha-Antitrypsin. Serum was obtained from tail veins or retroorbital plexus.
Culture supernatants were obtained at indicated time points. hAlb, human
transferrin, and human alpha-antitrypsinwere quantified using sandwich ELISA
methods (Bethyl Labs).
Urea Assay. Urea concentration in culture supernatants was measured using a
colorimetric assay based on the diacetyl-monoxime method (catalog no.
0580–250; Standbio Labs).
Flow Cytometry. Cells were fixed and stained for human and mouse CD81;
human leukocyte antigen (HLA)-A, B, C (BD Biosciences) and RFP expression
were measured on an LSRII flow cytometer (BD Biosciences) as described
previously (29). Data were analyzed using FlowJo software.
Fluorescence Staining and Imaging. For immunofluorescence staining, mpPHH
cultures were fixed and stained using as primary antibodies a rabbit poly-
clonal anti-NuMa antibody (catalog no. ab97585; Abcam) and a mouse
monoclonal anti-CK18 antibody (catalog no. ab82254; Abcam). AlexaFluor
488 and 594 (Thermo Fisher) of the corresponding species were used as
secondary antibodies. Nuclei were stainedwith DAPI. Cells were imaged using
a Nikon Eclipse TE300 fluorescent microscope and processed using ImageJ.
RNA Extraction and Library Preparation. Total RNA was isolated using TRIzol
(catalog no. 15596026; Thermo Fisher) followed by cleaning with RNeasy kit
(catalog no. 74104; Qiagen) coupled with on-column DNase I treatment
(catalog no. 79254; Qiagen); 250 ng of the DNase-treated RNA was used to
generate strand-specific sequencing libraries using TruSeq Stranded mRNA
Library Prep (catalog no. 20020594; Illumina). Multiplexed libraries were
sequenced as 50-nt single-end reads on a HiSeq2500 system (Illumina) at the
Rockefeller University Genomics core facility.
RNA-sequencing Bioinformatics Pipeline. Transcript alignment and quantifica-
tion were done using Kallisto (33). Transcript indices for Kallisto were gener-
ated from Ensembl release hg38 and included all annotated complementary
DNA and noncoding RNA transcripts. Differential expression analysis was then
done using Sleuth (34). Gene names and attributes were queried from Ensembl
using biomaRt. For genes containing multiple transcripts, we chose the tran-
script with the highest mean expression across all samples as the representative
example for that gene. Heat maps were generated in R Studio.
Statistical Analyses.Groups were compared by the Student t test. Correlations
were calculated using the Spearman correlation coefficient. All statistical
analyses were done using Prism 8 software (Graphpad).
Data Availability. Datasets supporting the findings of this study have been
deposited in a publicly available database (Gene Expression Omnibus accession
no. GSE130219).
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